VahatiCor Inc

About VahatiCor Inc

VahatiCor Inc. is a medical technology company founded in 2018 by Marwan Berrada Sounni and headquartered in Santa Clara, California. The company is focused on developing solutions for patients with Coronary Microvascular Dysfunction (CMD), a condition causing chest pain despite the absence of significant blockages in major coronary arteries. VahatiCor operates as a portfolio company of T45 Labs.

The company's core product is the A-FLUX Reducer System®, an investigational coronary sinus reducer implant designed to treat CMD. This minimally invasive, self-expanding device is placed in the coronary sinus to create a controlled narrowing, which optimizes and redistributes oxygenated blood flow to the heart muscle. This process is intended to enhance myocardial perfusion and relieve chronic symptoms like angina and shortness of breath. Key features of the A-FLUX system include its repositionable design, which enhances procedural safety, and a dense nitinol mesh that allows for immediate flow diversion. Unlike some existing technologies, it is designed to anchor with a low outward force, reducing risks of vessel damage.

VahatiCor's business model centers on the development and eventual commercialization of the A-FLUX system. The company is currently in the clinical trial phase, with the SERRA-I early feasibility study underway to evaluate the device's safety and efficacy in up to 30 patients across six sites. The first-in-human implant was successfully performed in early 2024 under Health Canada's Special Access Program. In November 2025, VahatiCor closed a $23 million Series B financing round led by S3 Ventures with support from Intuitive Ventures to fund clinical studies, engineering development, and preparations for pivotal trials.